Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.75% | 14.35% | 6.01% | -43.78% | -78.11% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -42.72% | 48.28% | 18.62% | 12.01% | -3.70% |
| Change in Net Operating Assets | -111.39% | -190.74% | -121.08% | -447.56% | 458.37% |
| Cash from Operations | 23.33% | -39.22% | -30.95% | -161.80% | -33.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 50.71% | -112.13% | -108.52% | 167.77% | 132.03% |
| Cash from Investing | 50.71% | -112.13% | -108.52% | 167.77% | 132.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -8.00% | -- | 27.17% | -- | -9.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -331.33% | -- | 27.17% | -- | -9.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.11% | -668.76% | -90.67% | 170.93% | 428.28% |